The global enteral nutrition market size was USD 7803.5 million in 2023. The global market for enteral nutrition was credited at USD 8693.3 million in 2025 The demand for enteral nutrition increased rapidly in recent 2024 at 5.9% YoY. The global sales during the forecast period (2025-2035) is expected to grow at a CAGR of 6.1, with a sales value reaching USD 15699.5 million by the end of 2035.
Enteral Nutrition Market Outlook: The market is largely driven by the rising burden of chronic diseases, a rapidly aging population, and an increasing focus on nutritional care for patients. Enteral nutrition, the provision of nutrients right to the gastrointestinal tract, is commonly used by hospitals, other long-term care facilities and home health care.
This market includes anything from standard formulae to disease-specific formulae to specialized feed for those with diabetes, cancer, and gastrointestinal disorders. Key players such as Abbott Laboratories, Nestlé Health Science, Danone, and Fresenius Kabi are increasingly investing in innovation, developing more palatable, nutrient-rich solutions and condition-specific formulations catering to both, the patients and healthcare industrialists.
| Attributes | Description |
|---|---|
| Estimated Industry Size (2025E) | USD 8693.3 million |
| Projected Industry Value (2035F) | USD 15699.5 million |
| Value-based CAGR (2025 to 2035) | 6.1% |
The transition from parenteral to enteral nutrition, owing to its lower complication rates and cost-effectiveness, is another factor assisting market growth. Moreover, high adoption of technology-based feeding devices and growing awareness related to clinical nutrition in developing economies is also raising the adoption.
Explore FMI!
Book a free demo
The table below provides an overview of the levels of growth rate fluctuation of CAGR over a period of six months for base year, 2024, and market year, current year, 2025, for the global enteral nutrition sector. The findings from this analysis underscore key changes in market performance and revenue trends, providing stakeholders with enhanced visibility into growth trajectories.
| Particular | Value CAGR |
|---|---|
| H1 (2024 to 2034) | 5.9% |
| H2 (2024 to 2034) | 6.0% |
| H1 (2025 to 2035) | 6.0% |
| H2 (2025 to 2035) | 6.1% |
For the North America in the Food Additives industry, the market for 2025 to 2035 is segmented into H1: 2025 to 2035 and H2: 2025 to 2035. The H1: 2025 to 2035 is expected to demand 6.0% CAGR during the period whereas the H2: 2025 to 2035 is expected to flatten out to 6.1% CAGR. During the subsequent time, H1 2025 to H2 2035, the CAGR is forecasted to constant growth. Facing growing clinical awareness, continued R&D on its specialized nutrition, and the increasing relevance of nutritional therapy on chronic disease management, the market is set for expansion.
In Tier 1, major players in the enteral nutrition market are global healthcare and nutrition giants with high revenue, strong clinical research capability, as well as wide spread hospital and home care networks. These companies manufacture complete, balanced formulations for patients who cannot consume oral nutrition due to medical conditions.
One of the leading players is Nestlé Health Science, which offers a variety of enteral nutrition products (Isosource & Peptamen) for patients with different gastrointestinal needs. Abbott Laboratories dominate both the clinical and home-based nutrition segment, with its well known Ensure and Glucerna lines.
Danone Nutricia also has a strong position with products like Fortimel and Nutrison addressing nutritional needs for pediatric, adult, and geriatric populations. Tier 1 players have strong clinical trial pipelines, global regulatory approval, and partnerships with healthcare providers.
Tier 2 comprises mid-size companies with market share growth, regional leadership, and niche/targeted nutrition expertise. Fresenius Kabi manufactures enteral feeding systems and devices primarily in Europe and Asia, for use with patients in the intensive and chronic care settings.
Reckitt Benckiser, which merged with Mead Johnson Nutrition, provides pediatric enteral nutrition products with advanced protein blends and immune-supportive formulas. These companies compete on the basis of cost-effective offers, products specific to the region, and strong distribution channels in the hospital and retail industries.
Tier 3 includes emerging and niche players with a concentration on specialty formulations, organic enteral nutrition, or condition-specific solutions. They range from startups and local manufacturers to clean-label, allergen-free or plant-based offerings. Kate Farms, for instance, manufactures organic, plant-based enteral nutrition formulas that are free of common allergens, targeting patients with food sensitivities and with chronic illness.
Other niche companies rely on e-commerce distribution strategies, offer personalized products and work directly with healthcare providers. Various factors are also responsible for the growth of this market such as the aging population, growing prevalence for chronic diseases such as diabetes and demand for home enteral tube feeding. Tier 1, 2, and 3 companies are doubling down on personalization, improved palatability, and clinically validated ingredients to improve patient outcomes and adapt to evolving medical nutrition needs.
Rise in Aging Population and Chronic Disease Prevalence
Shift: Japan, Western Europe, and North America have observed a rise in geriatric populations, leading to demand for enteral nutrition as an essential support tool for chronic conditions, dysphagia, and post-surgery recovery. Also, increasing number of diseases including cancer, stroke disease and neurological disease need nutritional therapy for long-term.
Strategic Response: Nestlé Health Science, Abbott and Danone Nutricia are among companies that have grown their clinical nutrition presentations with formulations tailored to metabolic requirements for age. Fresenius Kabi and Baxter are improving formulations for use in cancer care and ICU patients, such as high-protein and immunonutrition products that aid quicker recovery and immune function.
IHT for Enteral Nutrition and the Growth of Outpatient Management
Shift: Health care systems are increasingly moving to care at home or in outpatient settings in order to lower hospital costs and have patients’ care be more comfortable. This transition has increased the need for portable, user-friendly and long-term tube feeding solutions.
Strategic Response: Nestlé’s Compleat and Isosource; Abbott’s Jevity and Osmolite These companies have introduced long-lasting formulations and home-friendly packaging. B. Braun has built its homecare service network throughout Europe. Danone introduced remote nutritionist support through its UK Nutricia Homeward platform for patients and caregivers.
Growth of Pediatrics Nutrition and Neonatology Applications
Shift: Increased diagnosis of pediatric GI disorders, congenital abnormalities, and malnutrition is broadening the utilization of enteral nutrition in neonatal and pediatric care. The focus is on formulas that promote growth, brain development and immunity.
Strategic Response: Abbott’s PediaSure and EleCare are for children with special dietary needs. Neocate by Nutricia is the global leader in hypoallergenic infant enteral nutrition. Companies such as Mead Johnson (Reckitt) have centered their strategy around expanding hypoallergenic and amino-acid-based feeds for infants with cow milk protein allergy and eosinophilic conditions.
Increasing Demand for Specialized and Disease-Specific Formulas
Shift: The demand is increasing for condition-specific enteral formulas targeting renal disorders, liver disease, diabetes, oncology care, and pulmonary conditions.
Strategic Response: This strategic adaptation includes Fresubin Renal, Glucerna (Guss) for diabetic patients, Isosource HN (Nestlé) for cancer patients with a high-nutrient demand, among others. They include those modified for macronutrient, fibrous, or electrolyte content. Kate Farms manufactures plant-based, organic enteral formulas for critical illness and chronic care.
Link Between Technological Advancements in Feeding Equipment and High-Quality Performance
Shift: The trend across hospitals and homecare for more intelligent, portable, and safer enteral feeding equipment has acquired momentum, especially in ICUs. Developments in measurement facility, tubing protection, and control UI are combination of work items.
Strategic Response: Moog Inc. and Avanos Medical make smart pumps equipped with real-time monitoring and safety lockout systems. Cardinal Health has also created smart enteral devices and kits for patient hospital-to-home transitions. Innovations in feeding tubes such as ENFit connectors are globally embracing better ways to administer medication and formula.
In PCR period, there is a contraction for revenue in Segment - Tube-Free Oral Nutritional Supplements (ONS)
Shift: In the outpatients setting, oral nutritional supplements (ONS) have established themselves as the enteral nutrition modality of choice. Demand comes from cancer patients, elderly who have lost their appetite, and post-surgical cases.
Strategic Response: Make sure (Abbott) and Boost (Nestlé) dominate ONS with calorie-dense protein-rich drinks. Fresenius Kabi and Danone Nutricia have different taste profiles and functional derivatives (Fiber-rich, Karlie protein, Sugar-free). In Western markets we see increasing innovation in plant-based ONS and liquid meal replacements.
Changes to Reimbursement and Regulatory Landscape
Shift: Enteral Products in a report published by the "center of health economics" (an independent research body dedicated to researching the economic aspects of health care) has provided a detail report on the enteral nutrition market which drive the enteral nutrition market mainly depends on the insurance coverage and the reimbursement practices followed in the insurance of the patients in different parts of the world such as the U.S, EU and Japan. There are regulatory efforts underway to critically assess formulations and delivery methods for ensuring patient safety.
Strategic Response: Abbott, Fresenius and Nestlé actively engage with healthcare payers to get favorable reimbursement terms. With FDA, EMA and PMDA approvals in hand, companies are standardizing their labeling, allergen declarations, and clinical evidence. Various industry groups are pushing to expand coverage for oral and home-based enteral products.
Plant-Based Foods and Organic Ingredients Integration
Shift: With the continued push toward clean-label trends for even the most specialized sectors, we're seeing a move toward organic, allergen-free, and plant-based enteral formulations in clinical nutrition. These offerings are favored by patients with sensitivities or ethical dietary preferences.
Strategic Response: Kate Farms is the USA market leader in organic, non-GMO and allergen-free enteral formulas. BOOST brand Plant-Based Oral Nutritional Beverages Innovative science-based products for the management of the diabetic patient. Functional blends featuring turmeric, ginger, and MCTs are being released to fuel inflammation, digestion, and cognitive health.
Packaging Waste and Sustainability
Shift: Hospitals and consumers want eco-friendly packaging and ways to reduce medical waste tied to single-use feeding bags, bottles and cartons.
Strategic Response: Nestlé and Abbott are investigating recyclable, BPA-free (or Bisphenol A-free), and lighter packaging options for their enteral nutrition products. Danone recently pledged to make all its Nutricia products 100% recyclable or reusable by 2026. Hospitals are collaborating with vendors on recycling programs and green certifications.
Increase Country Penetration in Emerging Markets
Shift: The enteral nutrition market is witnessing significant demand in emerging countries such as India, Brazil, China, and Southeast Asia, owing to urbanization and the increasing middle-class income coupled with government healthcare infrastructure investments.
Strategic Response: Abbott and Nestlé are building up localized manufacturing and distribution networks throughout APAC and Latin America. Danone Nutricia India has also released smaller pack sizes of pediatric and adult enteral formulas to help with affordability." Fresenius Kabi also is establishing regional production hubs to tackle pricing and access barriers.
Virtual Care and Technology Use for Patients on Enteral Therapy
Shift: The post-pandemic era has propelled the embrace of telehealth services, digital tracking, and patient education platforms for enteral nutrition.
Strategic Response: Nutricia Homeward (UK) and Abbott Nutrition Support Platforms provide remote patient consultations with dietitians, adherence monitoring of patients remotely, and mobile apps for tracking dosage. To design enteral nutrition customized to disease profile and caloric requirement, the startups are rolling out AI-based nutrition calculators.
Management of Pediatric Allergy and Intolerance
Shift: Enteral elimination diets and amino acid-based feeds are being used more often to manage food allergies and intolerances in children.
Strategic Response: Neocate (Nutricia), EleCare (Abbott) and PurAmino (Mead Johnson) are top among hypoallergenic amino-acid formulas. These products are vital to children with multiple food allergies, eosinophilic esophagitis, and other severe GI conditions.
The following table outlines the estimated compound annual growth rates (CAGR) for the top five high-potential markets for enteral nutrition:
| Countries | CAGR (2025 to 2035) |
|---|---|
| USA | 5.8% |
| Germany | 6.4% |
| China | 6.7% |
| Japan | 5.9% |
| India | 7.2% |
The enteral nutrition market in the USA is growing rapidly owing to a growing geriatric population, as well as rising prevalence of chronic diseases including cancer, gastrointestinal diseases and neurological disorders. Hospitals and long-term care facilities are major demand drivers, while continued movement toward home healthcare is bringing tube-feeding formulas into the noninstitutional realm.
Customized nutritional support has been increasingly used as part of a patient-focused approach to the healthcare system in the USA to better clinical outcomes in the perioperative and critical care environments. The trust in the market has been strengthened with the advancements in enteral feeding devices with better safety standards and more awareness among caregivers.
Insurance reimbursement programs that include nutritional therapy and feeding devices create further incentives for these therapies. Research advancements in formula design- including disease-specific, high-protein, fiber-enriched, or plant-based formulations-are transforming the approach to nutritional therapy across multiple care environments.
Enteral nutrition market in China is showing strength, and the modernisation of healthcare infrastructure at a rapid pace combined with the rising awareness of hospital-acquired malnutrition all are pushing the market demand robustly. Investments made by the country towards their clinical nutrition programs, its growing adoption of enteral nutrition in the patient’s treatment protocols by hospitals, mainly in surgical recovery, oncology, and critical care units.
It also benefited from better education and training of health care providers and standardization of protocols for the provision of nutritional support. The government-backed health reforms and broader coverage of insurance have made patients avail medical nutrition at low rates.
The large number of aged population and the increasing burden of chronic diseases are still determining market demand needs, whereas locally produced and imported premium-products are available for cost-sensitive or high-end hospitals. The need to prevent or to improve nutritional status of patients at a tertiary level care has great potential which may become even larger with continued urbanization of China.
The enteral nutrition industry in India is in a state of rapid evolution, keyed to the incidences of chronic disease, improved access to healthcare, and an increasing number of surgical procedures demanding nutritional intake post-operatively. This demand is especially pronounced in ICUs, oncology wards, and neurology departments, where nutritional support is an integral part of recovery.
MakeEnteral is secondary product of PT ABC Company, which supplies affordable, enteral formula products in the face of rising demand from government and private hospital networks for locally manufactured enteral formulations. Moreover, the adoption of targeted government efforts focused on tackling malnutrition and enhancing healthcare infrastructure is also driving the growth of the clinical nutrition market.
The growth of private hospital chains in Tier 2 and Tier 3 cities and an increasing focus on long-term patient care and rehabilitation are also aiding the market. The country has significant diabetic and geriatric populations that enable it to emerge as a major market for specialized enteral formulations addressing specific health conditions. Local companies are innovating quickly on product development while boosting distribution via pharmacies and digital health platforms.
| Segment | Value Share (2025) |
|---|---|
| Standard Formula (By Product Type) | 47.6% |
Enteral nutrition market is widely covered by standard formulas, primarily due to the well tolerance, nutrition composition and wider applicability in patient demographics. These formulas are designed to be complete, providing both daily macronutrient and micronutrient requirements, and are typically used for patients who are unable to consume food normally, but have no serious dysfunction of their gastrointestinal organs.
Many adult patients in hospitals and home health care settings have an increasing need for nutritional support as their numbers continue to grow, including elderly patients, post-operative patients, and those with chronic diseases (eg, cancer, neurological). Standard enteral formulas are utilized as a solution to meet this need in adult populations.
But major brands have branched out, with fiber-rich and calorie-packed products to meet specific caloric and digestive needs. And their market dominance has grown from the convenience these formulations offer and clinical endorsements and insurance coverage in many countries. Healthcare systems are increasingly focusing on nutritional management as an integral component of recovery and wellness, which is anticipated to contribute to a stable uptake of standard formulas across the forecast period.
| Segment | Value Share (2025) |
|---|---|
| Tube Feeding (By Feeding Route) | 68.2% |
With the advances in enteral nutrition, tube feeding is increasingly being utilized as the route of choice, especially during critical illness, in long-term care, as well as post-operatively. Enteral formula products provide predicted protein, calorie and micronutrient content Strictly, the method guarantees that nutrients in the digestive tract are delivered through nasogastric, gastrostomy or jejunostomy tubes, this is particularly needed in the scenario of impaired swallowing (dysphagia), coma or gastrointestinal cancers.
As chronic conditions like stroke, Alzheimer’s and head and neck cancers increase, demand for tube feeding is on the rise in both hospital- and home-based settings. Advances in technology for enteral pumps, and feeding tube materials, have made administration more comfortable as well as more discreet and safer. As a result of this increased confidence amongst health professionals to initiate and manage enteral tube feeding protocols, acceptance amongst patients is expanding.
In addition, as developed markets have reimbursed tube feeding as cost-effective for long-term care, they have become the only option for many. On the other hand, developing economies are experiencing growth fueled by increases in healthcare access and awareness efforts. As enteral nutrition is increasingly embedded into clinical pathways, tube feeding remains the method of choice for the prolonged delivery of nutritional therapy.
Key manufacturers for enteral Nutrition include Nestlé SA, Fresenius Kabi AG, B. Braun SE, with global reach, Medical nutrition expertise and innovation in formulations and delivery systems. They are well established with a broad portfolio of enteral feeding products meeting patient needs from critical care, chronic disease, large specialized nutrition formulas to age specific Nutrition. This clinical validation, consideration of patient safety, and compatibility of enteral feeding devices set them apart in the market.
Make significant investments in R&D, while establishing partnerships with key healthcare institutions to strengthen distribution network and diversify product portfolio With strategic acquisitions. This was key to the increasing demand for home-based care and personalized nutrition across markets worldwide.
For instance:
In a competitive landscape, other prominent participants including Aveanna Healthcare, Danone SA, Reckitt Benckiser Group PLC, Medtrition Inc., Victus Inc., Kate Farms, Global Health Products, Inc., and DermaRite Industries, LLC are strengthening their foothold through innovations in clean-label formulations, plant-based alternatives, and disease-specific nutritional solutions. Other companies focus on sustainably sourcing materials and following medical standards to guarantee both the effectiveness and the ethical responsibility of their products.
These manufacturers are pivotal in the development of enteral diets for alternate delivery routes, as the enteral nutrition market grows with the aging population and rising chronic diseases.
The global industry is estimated at a value of USD 8693.3 million in 2025.
Sales increased at a 5.2% CAGR between 2020 and 2024.
Some of the leaders in this industry include Nestle SA, Fresenius Kabi AG, Danone SA, B. Braun SE, Abbott Nutrition, Aveanna Healthcare, Reckitt Benckiser Group PLC, Medtrition Inc., Victus Inc, Kate Farms, Global Health Products, Inc., DermaRite Industries, LLC.
Key end-use segments include hospitals, home care settings, and long-term care facilities, with hospitals holding a dominant share in 2025 due to the high volume of inpatient treatments.
The industry is projected to grow at a forecast CAGR of 6.1% from 2025 to 2035.
In this segment, the industry has been categorized into Standard Formula, Peptide-Based Formula, disease-specific and others
By feeding route industry has been categorized into tube feeding and oral feeding.
Different demographics of consumers like Pediatrics and Adults are included in the report.
By End Users, the industry has been categorized into Hospitals, Home Care, Long Term Care facilities, Nursing Homes
Industry analysis has been carried out in key countries of North America, Latin America, Western Europe, Eastern Europe, Balkans & Baltic, Russia & Belarus, Central Asia, East Asia, South Asia & Pacific, and the Middle East & Africa.
Market Outlook of Omega-3 Pet Supplement by Pet, Type, Form, Application and Other Types Through 2035
Extra Neutral Alcohol (ENA) Market Analysis – Growth, Applications & Outlook 2025-2035
Analysis and Growth Projections for Arrowroot Starch Market
Analysis and Growth Projections for Fructo-Oligosaccharides Market 2025 to 2035
Analysis and Growth Projections for Beverage Flavoring Agent
Plant-Based Collagen Market Analysis by Sources, Form and End-use Industry Through 2035
Enteral Nutrition Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
